中华皮肤科杂志 ›› 2025, Vol. 58 ›› Issue (11): 1059-1063.doi: 10.35541/cjd.20250269

• 论著 • 上一篇    下一篇

银屑病患者生物制剂认知、治疗需求与慢病管理优化路径的横断面研究

王帆1    邢小怡1    王蕊2    刘欢2    刘茜2    俞晨2   

  1. 1西安医学院研究生工作部，西安  710068；2空军军医大学西京医院皮肤科，西安  710032 
  • 收稿日期:2025-05-13 修回日期:2025-09-14 发布日期:2025-11-03
  • 通讯作者: 俞晨 E-mail:ycyc_2005@163.com
  • 基金资助:
    陕西省重点研发计划项目（2024SF-YBXM-284）

A cross-sectional study on knowledge, treatment needs, and optimization of chronic disease management pathways regarding biologics in patients with psoriasis

Wang Fan1, Xing Xiaoyi1, Wang Rui2, Liu Huan2, Liu Qian2, Yu Chen2   

  1. 1Office of Graduate Student Affairs, Xi'an Medical University, Xi'an 710068, China; 2Department of Dermatology, Xijing Hospital, Air Force Medical University, Xi′an 710032, China
  • Received:2025-05-13 Revised:2025-09-14 Published:2025-11-03
  • Contact: Yu Chen E-mail:ycyc_2005@163.com
  • Supported by:
    Key Research and Development Program of Shaanxi Province（2024SF-YBXM-284）

PDF

0

摘要： 【摘要】 目的 探讨银屑病患者对生物制剂的认知特征、影响因素及其治疗需求。方法 采用横断面研究设计，选取2022年10 - 12月及2023年6 - 12月于空军军医大学西京医院皮肤科门诊就诊的银屑病患者，采用自主设计的电子问卷进行调查。问卷内容包括人口学特征、银屑病疾病史（疾病类型、病程、既往治疗等）、生物制剂知识水平（知晓途径、核心认知维度）及治疗需求等。结果 有效问卷回收率为93.2%（439/471），入组患者年龄（35.95 ± 12.57）岁，病程（7.90 ± 3.26）年，且以寻常型银屑病为主（363例，82.69%）。生物制剂总体知晓率由2022年68.62%（105/153）升至2023年72.38%（207/286）（P > 0.05）。信息获取主渠道为新媒体（微信/网络）平台（168例，53.84%）及病友经验分享（115例，36.86%），医师主导告知仅29例，占9.29%（P < 0.001）。对生物制剂的认知不足突出表现为共病知识知晓率低（47.60%，209/439），治疗监测知晓率低（22.32%，98/439）。患者治疗需求核心关注点包括安全性（73.34%，322/439）、经济负担（65.14%，286/439）及疗效持久性（63.55%，279/439），60.13%（264/439）期望皮肤症状快速改善；治疗方式方面，90.20%（396/439）倾向延长给药间隔方案。结论 银屑病患者存在生物制剂认知结构失衡现象，患者治疗需求呈现多维特征，在追求皮损快速清除的同时，更重视治疗安全性与成本效益。

关键词: 银屑病, 生物制剂, 认知现状, 治疗需求, 患者教育

Abstract: 【Abstract】 Objective To explore the cognitive characteristics, influencing factors, and treatment needs regarding biologic agents among patients with psoriasis. Methods A cross-sectional study was conducted. Patients with psoriasis attending the Department of Dermatology, Xijing Hospital, Air Force Medical University were selected from October to December 2022, and from June to December 2023. A self-designed electronic questionnaire was used for investigation, covering demographic characteristics, psoriasis history （disease types, disease duration, previous treatments, etc.）, biologics knowledge （sources of awareness, core cognitive dimensions）, and treatment needs. Results The valid questionnaire response rate reached 93.2% （439/471）. The ages of enrolled patients were 35.95 ± 12.57 years, and the disease duration was 7.90 ± 3.26 years. Psoriasis vulgaris was the predominant type （363 cases, 82.69%）. The overall awareness rate of biologics slightly increased from 68.62% （105/153） in 2022 to 72.38% （207/286） in 2023 （P > 0.05）. Primary information sources included new media （WeChat/internet） platforms （168 cases, 53.84%） and peer-to-peer sharing （115 cases, 36.86%）, while physician counseling merely accounted for 9.29% （29 cases） （P < 0.001）. Insufficient knowledge of biologics was manifested primarily as poor awareness of comorbidities （47.60%, 209/439） and treatment monitoring protocols （22.32%, 98/439）. Core concerns regarding biologic therapy included safety （73.34%, 322/439）, economic burden （65.14%, 286/439）, and long-term efficacy （63.55%, 279/439）; 60.13% （264/439） of the patients expected rapid improvement of skin symptoms. As for treatment modalities, 90.20% （396/439） of the patients preferred regimens with extended dosing intervals. Conclusions The patients with psoriasis demonstrated an imbalance in their cognitive structure regarding biologic agents. Their treatment needs exhibited multidimensional characteristics, emphasizing not only rapid clearance of skin lesions but also greater importance of treatment safety and cost-effectiveness.

Key words: Psoriasis, Biological agent, Cognitive status, Treatment demands, Patient education

引用本文

王帆 邢小怡 王蕊 刘欢 刘茜 俞晨. 银屑病患者生物制剂认知、治疗需求与慢病管理优化路径的横断面研究[J]. 中华皮肤科杂志, 2025,58(11):1059-1063. doi:10.35541/cjd.20250269

Wang Fan, Xing Xiaoyi, Wang Rui, Liu Huan, Liu Qian, Yu Chen. A cross-sectional study on knowledge, treatment needs, and optimization of chronic disease management pathways regarding biologics in patients with psoriasis[J]. Chinese Journal of Dermatology, 2025, 58(11): 1059-1063.doi:10.35541/cjd.20250269